Wolin EM, Manon A, Chassaing C, et al.Bethesda, MD: National Institutes of Health Clinical Center July 2016. Presented at the 101st Annual Meeting and Expo of the Endocrine Society. Enhancing patient care: co-creation and validation of a new and improved delivery system for lanreotide autogel/depot and its evaluation by US healthcare professionals. Adelman DT, Truong Thanh X-M, Mégret C.Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis. Basking Ridge, NJ: Ipsen Biopharmaceuticals, Inc. Evaluation of nurse preferences between the lanreotide autogel new syringe and the octreotide long-acting release syringe: an international simulated-use study (PRESTO). Adelman D, Truong Thanh X-M, Feuilly M, Houchard A, Cella D.Basking Ridge, NJ: Ipsen Biopharmaceuticals, Inc 2022. Evaluation of lanreotide depot/autogel efficacy and safety as a carcinoid syndrome treatment (ELECT): a randomized, double-blind, placebo-controlled trial. Vinik AI, Wolin EM, Liyanage N, Gomez-Panzani E, Fisher GA on behalf of the ELECT Study Group.Lanreotide in metastatic enteropancreatic neuroendocrine tumors. Caplin ME, Pavel M, Ćwikła JB, et al, for the CLARINET Investigators.Cambridge, MA: Ipsen Biopharmaceuticals, Inc. Somatuline Depot (lanreotide) Injection.Please click here for the full Prescribing Information and Patient Information. the treatment of adults with carcinoid syndrome when used, it reduces the frequency of short-acting somatostatin analog rescue therapy.the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival and.SOMATULINE ® DEPOT (lanreotide) is a somatostatin analog indicated for: To report SUSPECTED ADVERSE REACTIONS , contact Ipsen Biopharmaceuticals, Inc. Lactation: Advise women not to breastfeed during treatment and for 6 months after the last dose.SOMATULINE DEPOT may decrease the absorption of cyclosporine (dosage adjustment may be needed) increase the absorption of bromocriptine and require dosage adjustment for bradycardia-inducing drugs (e.g., beta-blockers).Adverse reactions in ≥5% of patients who received SOMATULINE DEPOT and at least 5% greater than placebo were headache (12%), dizziness (7%) and muscle spasm (5%). Carcinoid Syndrome: Adverse reactions occurring in the carcinoid syndrome trial were generally similar to those in the GEP-NET trial. GEP-NETs: Adverse reactions in >10% of patients who received SOMATULINE DEPOT were abdominal pain (34%), musculoskeletal pain (19%), vomiting (19%), headache (16%), injection site reaction (15%), hyperglycemia (14%), hypertension (14%), and cholelithiasis (14%).Care should be taken when initiating treatment in patients with bradycardia. In patients suffering from cardiac disorders prior to treatment, sinus bradycardia may occur.In patients without underlying cardiac disease, SOMATULINE DEPOT may lead to a decrease in heart rate without necessarily reaching the threshold of bradycardia.SOMATULINE DEPOT may decrease heart rate.Blood glucose levels should be monitored when SOMATULINE DEPOT treatment is initiated, or when the dose is altered, and antidiabetic treatment should be adjusted accordingly.Patients treated with SOMATULINE DEPOT may experience hypoglycemia or hyperglycemia.If complications of cholelithiasis are suspected, discontinue SOMATULINE DEPOT and treat appropriately.SOMATULINE DEPOT may reduce gallbladder motility and lead to gallstone formation.Allergic reactions (including angioedema and anaphylaxis) have been reported following administration of lanreotide. SOMATULINE DEPOT is contraindicated in patients with hypersensitivity to lanreotide.IMPORTANT SAFETY INFORMATION & INDICATIONS Contraindications
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |